Evidence map›Paper›PMID 31992226›Full record

ArticleBMC cancer2020

NFкB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.

Chitrangda Srivastava, Khushboo Irshad, Yakhlesh Gupta, Chitra Sarkar, Ashish Suri, Parthaprasad Chattopadhyay, Subrata Sinha, Kunzang Chosdol

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. The Role ofInfection and drug resistance · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?Journal of experimental & clinical cancer research : CR · 2022
    Review
  10. Key Role of Astrocytes in Postnatal Brain and Retinal Angiogenesis.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Chitrangda SrivastavaDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Khushboo IrshadDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Yakhlesh GuptaDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Chitra SarkarDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Ashish SuriDepartment of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Parthaprasad ChattopadhyayDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Subrata SinhaDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Kunzang ChosdolDepartment of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India. kunzangchosdol@yahoo.com.ORCID http://orcid.org/0000-0002-7065-3395
All India Institute of Medical Sciences · INNational Institute of Environmental Health Sciences · US

Funding

Department of Biotechnology , Ministry of Science and Technology BT/PR13357/MED/30/1532/2015Indian Council of Medical Research 5/13/58/2014/NCD-III
6 · The paper itself

Abstract

backgroundOverexpression of FAT1 gene and its oncogenic effects have been reported in several cancers. Previously, we have documented upregulation of FAT1 gene in glioblastoma (GBM) tumors which was found to increase the expression of proinflammatory markers, HIF-1α, stemness genes and EMT markers in glioma cells. Here, we reveal NFкB (RelA)/RelA/p65 as the transcriptional regulator of FAT1 gene in GBM cells.

methodsIn-silico analysis of FAT1 gene promoter was performed using online bioinformatics tool Promo alggen (Transfac 8.3) to identify putative transcription factor(s) binding motifs. A 4.0 kb FAT1 promoter (- 3220 bp to + 848 bp w.r.t. TSS + 1) was cloned into promoter less pGL3Basic reporter vector. Characterization of FAT1 promoter for transcriptional regulation was performed by in-vitro functional assays using promoter deletion constructs, site directed mutagenesis and ChIP in GBM cells.

resultsExpression levels of NFкB (RelA) and FAT1 were found to be increased and positively correlated in GBM tumors (n = 16), REMBRANDT GBM-database (n = 214) and TCGA GBM-database (n = 153). In addition to glioma, positive correlation between NFкB (RelA) and FAT1 expression was also observed in other tumors like pancreatic, hepatocellular, lung and stomach cancers (data extracted from TCGA tumor data). A 4.0 kb FAT1-promoter-construct [- 3220 bp/+ 848 bp, transcription start site (TSS) + 1, having 17 NFкB (RelA) motifs] showed high FAT1 promoter luciferase-activity in GBM cells (U87MG/A172/U373MG). FAT1 promoter deletion-construct pGL3F1 [- 200 bp/+ 848 bp, with 3-NFкB (RelA)-motifs] showed the highest promoter activity. Exposure of GBM cells to known NFкB (RelA)-activators [severe-hypoxia/TNF-α/ectopic-NFкB (RelA) + IKBK vectors] led to increased pGL3F1-promoter activity and increased endogenous-FAT1 expression. Conversely, siRNA-mediated NFкB (RelA) knockdown led to decreased pGL3F1-promoter activity and decreased endogenous-FAT1 expression. Deletion of NFкB (RelA)-motif at - 90 bp/- 80 bp [pGL3F1δ1-construct] showed significant decrease in promoter activity. Site directed mutagenesis at -90 bp/- 80 bp and ChIP assay for endogenous-NFкB (RelA) confirmed the importance of this motif in FAT1 expression regulation. Significant reduction in the migration, invasion as well as colony forming capacity of the U87MG glioma cells was observed on siRNA-mediated knockdown of NFкB (RelA).

conclusionSince FAT1 and NFкB (RelA) are independently known to promote pro-tumorigenic inflammation and upregulate the expression of HIF-1α/EMT/stemness in tumors, targeting the NFкB (RelA)-FAT1 axis may attenuate an important tumor-promoting pathway in GBM. This may also be applicable to other tumors.

Indexed as

Binding SitesBrain NeoplasmsCadherinsCell Line, TumorCell MovementCloning, MolecularComputer SimulationGene Expression Regulation, NeoplasticGliomaHumansMutagenesis, Site-DirectedPromoter Regions, GeneticSignal TransductionTranscription Factor RelACadherinsFAT1 protein, humanRELA protein, humanTranscription Factor RelAFAT1GlioblastomaNFкB (RelA)PromoterTumor

Identifiers

PMID31992226
PMCPMC6988320
OpenAlexW3013190701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.